Health Care • Medical/Dental Instruments
$23.00 ▼ -0.50
(-2.13%)
MKT CAP: $12.15B • VOL: 11.82M
52W L $16 52W H $30
BAX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $11.24B | $10.64B | $10.36B |
| YoY Revenue Growth % | +5.7% | +2.7% | — |
| Gross Profit | $3.38B | $3.98B | — |
| Gross Margin % | 30.1% | 37.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$308.0M | $14.0M | $707.0M |
| Operating Margin % | -2.7% | 0.1% | 6.8% |
| Net Income (GAAP) | -$957.0M | -$649.0M | $2.66B |
| EBITDA (Normalized) | $96.8M | $396.9M | $1.08B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $845.0M | $1.02B | $1.73B |
| Capital Expenditures (CapEx) | $506.0M | $478.6M | $466.2M |
| Free Cash Flow (FCF) | $339.0M | $540.4M | $1.26B |
| FCF Margin % | 3.0% | 5.1% | 12.2% |
| Return on Invested Capital (ROIC %) | -2.3% | 0.1% | 7.4% |
| Cash & Short-Term Equivalents | $1.97B | $1.76B | — |
| Total Debt (Short + Long Term) | $6.28B | $8.44B | $2.91B |
| Total Stockholders' Equity | $6.13B | $6.96B | $5.97B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BAX.